This combination is indicated as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection. It is prescribed for both adults and children diagnosed with HIV-1. When taken regularly, it helps reduce viral load, strengthen the immune system, and slow disease progression, making it an important option in antiretroviral therapy.

This medication works through a multi-mechanism approach to block HIV replication. Dolutegravir is an integrase inhibitor that prevents viral DNA from integrating into the host cell’s genome. Lamivudine and tenofovir disoproxil fumarate are nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) that block the reverse transcriptase enzyme, preventing viral replication. Together, these drugs reduce the amount of virus in the body and help maintain immune system function.

This medication is available as a film-coated tablet containing 50 mg dolutegravir, 300 mg lamivudine, and 300 mg tenofovir disoproxil fumarate. The usual recommended dosage is one tablet taken once daily, with or without food. It should be taken at the same time every day for best results. Patients should follow their doctor’s instructions carefully and avoid missing doses to maintain consistent viral suppression.

Common side effects include insomnia, tiredness, headache, diarrhea, rash, cough, fever, and mood changes such as depression. These are usually mild and manageable. However, serious side effects may occur, including bone loss, kidney injury, worsening of hepatitis B infection, immune reconstitution syndrome, lactic acidosis, and liver enlargement or toxicity. Immediate medical attention is required if severe symptoms or allergic reactions occur.

This medication should not be used in patients with known hypersensitivity to dolutegravir, lamivudine, or tenofovir disoproxil fumarate. Caution is advised in patients with a history of pancreatitis, liver disease, kidney problems, heart conditions, or bone disorders. Regular monitoring of blood counts, liver function, kidney function, and bone health is recommended during treatment. Women of childbearing potential should use effective contraception, and this medication is generally not recommended during early pregnancy. Breastfeeding should be avoided due to the risk of HIV transmission.

Dolutegravir, lamivudine, and tenofovir disoproxil fumarate provide a convenient and effective once-daily treatment option for HIV-1 infection. By combining three powerful antiviral agents into a single tablet, it simplifies therapy and supports long-term viral control. While generally well tolerated, careful monitoring and adherence to treatment are essential for safety and effectiveness. With proper medical guidance, this combination plays a key role in modern HIV care.